| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.2596 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.2710 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.3362 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.3381 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.3590 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.3740 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.3952 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.3963 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.4158 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.4173 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.4216 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.4222 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.4630 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.4682 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.4840 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.4841 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.4881 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.4898 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.4898 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.4947 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.5009 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.5242 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.5259 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.5691 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.5691 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.5706 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.5742 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.5745 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.5843 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.6005 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.6092 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.6208 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.6285 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.6401 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.6491 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.6533 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.6630 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.6647 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.6833 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.6902 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.6949 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7077 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7097 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7195 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7262 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7338 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7351 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7356 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7378 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7442 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7620 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7675 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7682 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7707 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7711 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7725 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7740 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7761 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7802 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7829 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7835 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7884 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7903 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.7916 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8229 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8230 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8231 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8279 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8409 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8489 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8562 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8629 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8645 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8681 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8698 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8722 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8742 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8795 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8869 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8872 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8910 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.8917 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.9001 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.9002 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.9012 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.9126 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.9319 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.9350 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.9517 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.9522 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.9665 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.9770 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 0.9924 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.0000 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.0016 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.0076 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.0113 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.0113 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.0143 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.0165 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.0281 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.0375 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.0407 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.0523 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.0590 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.0858 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.0919 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.0929 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.1062 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.1068 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.1169 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.1189 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.1233 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.1431 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.1434 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.1451 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.1480 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.1648 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.1765 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.1855 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.1937 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.1990 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.1997 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.2010 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.2048 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.2061 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.2122 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.2205 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.2209 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.2391 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.2540 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.2567 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.2570 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.2684 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.2696 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.2929 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.2940 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.3009 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.3014 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.3090 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.3202 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.3273 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.3281 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.3337 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.3478 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.3493 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.3517 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.3714 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.3774 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.3779 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.4334 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.4358 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.4388 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.4471 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.4526 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.4560 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.4706 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.4764 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.4856 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.4859 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.5176 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.5436 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.5573 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.5714 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.5822 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.5900 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.5965 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.6140 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.6288 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.6826 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.6869 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.7226 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.7313 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.7791 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.7973 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.8037 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.8300 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.8342 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 1.8670 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 2.0204 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 2.0341 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 2.0740 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 2.1204 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 2.1279 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 2.2439 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 2.3165 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | laurate (12:0) | 3.8398 | scaled units | Low-Dose | -0.5HR |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|